Indications, dosing and sources of generic medicines
32 oncology, immunology and diabetes molecules with approved indications, mechanism, dosing and adjustments, side effects and monitoring, the manufacturer landscape, and availability across Southeast Asia.
Search by molecule, brand or manufacturer
32 molecules
Most requested molecules
Molecules most frequently requested and most widely used clinically — open one for the full monograph and manufacturer list.
| Molecule | Therapeutic area | Originator reference | Manufacturer records | |
|---|---|---|---|---|
| Osimertinib AstraZeneca | Lung cancer (EGFR) | Tagrisso | 14 | Open → |
| Crizotinib Pfizer | Lung cancer (ALK) | Xalkori | 10 | Open → |
| Palbociclib Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc) | Breast cancer | Ibrance | 5 | Open → |
| Olaparib AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada) | Ovarian cancer | Lynparza | 4 | Open → |
| Ibrutinib Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC | Blood cancer | Imbruvica | 11 | Open → |
| Adalimumab AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002) | Rheumatology / psoriasis | Humira | 9 | Open → |
| Tofacitinib Pfizer (initial U.S. approval 2012) | Rheumatology | Xeljanz / Xeljanz XR | 8 | Open → |
| Sofosbuvir/Velpatasvir Gilead Sciences (Gilead Sciences Ireland UC for the EU) | Hepatitis C | Epclusa | 12 | Open → |
Therapeutic areas
Cancer (oncology)
Targeted therapies and biosimilars for lung, breast, ovarian, blood and other solid tumours — the largest cost burden for patients in Southeast Asia.
15 molecules →Immunology & rheumatology
Biologics and JAK inhibitors for rheumatoid arthritis, psoriasis, ankylosing spondylitis, IBD and multiple sclerosis.
5 molecules →Diabetes & metabolic
DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists and insulin analogues — the highest-volume chronic therapy in the region.
11 molecules →Antivirals (hepatitis C)
Direct-acting antivirals that cure chronic hepatitis C in 12 weeks.
1 molecules →Leading manufacturers
How we build this database
① Authoritative base
Indications, dosing and adverse reactions come from FDA/EMA labels and national registries — nothing that cannot be traced back to a source.
② Manufacturers & brands
Every molecule records its generic and biosimilar manufacturers, brand names and strengths for cross-checking and source verification.
③ Availability
Registration and availability status across Southeast Asian markets, with unknowns marked as unknown rather than inferred.
④ Quarterly review
Content is re-verified quarterly; each page shows its last review date and full source list.
FAQ
Where does this information come from?
Indications, dosing and safety content comes from FDA/EMA labels, national drug registries (DGDA in Bangladesh, CDSCO in India and others) and peer-reviewed literature. Manufacturer and brand records come from public national drug registries, collected in September 2026. Every key statement is traceable to its source document.
Do you sell medicines on this site?
No. This is a knowledge and manufacturer-intelligence resource. We do not sell prescription medicines to individual patients and we do not give medical advice. We help licensed pharmacies, hospitals, importers and distributors verify manufacturers and connect to supply channels.
Why focus on Bangladesh and India?
Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption to 2033, so manufacturers there can legally produce molecules still under patent elsewhere; India is the world’s largest generic producer. Those two registration landscapes are the basis for knowing which sources exist for a molecule.
How do I verify the quality of a generic?
Four checks: does the manufacturer hold national GMP certification, is the product registered with the national regulator (DGDA, CDSCO, NPRA, FDA PH…), can the supplier provide the batch number and a certificate of analysis, and is the product traceable. Our manufacturer pages list each company’s brands and strengths for cross-checking.
Can you ship to my country?
We support sourcing routes into Bangladesh, India, Pakistan, Philippines, Malaysia, Singapore, Thailand, Vietnam, Indonesia, Nigeria, Kenya. Shipping and clearance run through a licensed importer in the destination country and require a prescription, the diagnostic report and an import permit. Tell us the destination before ordering and we will confirm the legal route.
How often is the content updated?
Safety information and manufacturer product lines change with new indications, label updates and discontinuations, so we re-verify quarterly; each page shows its last review date.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
